These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 30773618)
1. Research Projects Supported by the University of California, San Francisco-Stanford Center of Excellence in Regulatory Science and Innovation. Giacomini KM; Lin L; Altman RB Clin Pharmacol Ther; 2019 Apr; 105(4):815-818. PubMed ID: 30773618 [No Abstract] [Full Text] [Related]
2. The US Food and Drug Administration Centers for Regulatory Science and Innovation: Current Activities and Future Promise to Accelerate Innovations. Weichold FF Clin Pharmacol Ther; 2019 Apr; 105(4):792-794. PubMed ID: 30739310 [No Abstract] [Full Text] [Related]
5. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation. Honig P; Zhang L Clin Pharmacol Ther; 2019 Apr; 105(4):778-781. PubMed ID: 30883715 [TBL] [Abstract][Full Text] [Related]
6. Clinical Centers of Excellence: headache. University of California, San Francisco Headache Center. Bennett D Med Econ; 2009 May; 86(9):30. PubMed ID: 19526903 [No Abstract] [Full Text] [Related]
7. Camelot or common sense? The logic behind the UCSF/Stanford merger. Van Etten P Health Aff (Millwood); 1999; 18(2):143-8. PubMed ID: 10091441 [TBL] [Abstract][Full Text] [Related]
8. Academy: strengthening the educational mission in academic health centers. Howell TH; Karimbux NY J Dent Educ; 2004 Aug; 68(8):845-50. PubMed ID: 15286107 [TBL] [Abstract][Full Text] [Related]
9. The role of academic medical centers in advancing regulatory science. Meyer RJ Clin Pharmacol Ther; 2014 May; 95(5):471-3. PubMed ID: 24747233 [TBL] [Abstract][Full Text] [Related]
10. Case study: the Stanford University School of Medicine and its teaching hospitals. Pizzo PA Acad Med; 2008 Sep; 83(9):867-72. PubMed ID: 18728444 [TBL] [Abstract][Full Text] [Related]
11. UCSF/Stanford: building a 'prestige cartel'. Goldsmith J Health Aff (Millwood); 1999; 18(2):149-51. PubMed ID: 10091442 [No Abstract] [Full Text] [Related]
12. University-based science and biotechnology products: defining the boundaries of intellectual property. Kesselheim AS; Avorn J JAMA; 2005 Feb; 293(7):850-4. PubMed ID: 15713775 [TBL] [Abstract][Full Text] [Related]
13. Implications of the hospitalist movement for academic departments of medicine: lessons from the UCSF experience. Wachter RM; Goldman L Am J Med; 1999 Feb; 106(2):127-33. PubMed ID: 10230739 [No Abstract] [Full Text] [Related]
14. Fraud, conflict of interest, and other enforcement issues in clinical research. Sheehan JG Cleve Clin J Med; 2007 Mar; 74 Suppl 2():S63-7; discussion S68-9. PubMed ID: 17471620 [TBL] [Abstract][Full Text] [Related]
15. Biomedical policy. U.S. House reveals ambitious biomedical innovation plan. Servick K Science; 2015 Feb; 347(6222):594-5. PubMed ID: 25657222 [No Abstract] [Full Text] [Related]
16. Clinical centers of excellence: dermatology. University of California, San Francisco Medical Center. Campbell ML Med Econ; 2009 Jan; 86(2):21. PubMed ID: 19271585 [No Abstract] [Full Text] [Related]
17. Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research. Rothenburg ML; Johnson DH JAMA Oncol; 2017 Dec; 3(12):1621-1622. PubMed ID: 28687825 [No Abstract] [Full Text] [Related]
18. The University of California at San Francisco Fetal Treatment Center: a personal perspective. Harrison MR Fetal Diagn Ther; 2004; 19(6):513-24. PubMed ID: 15539877 [TBL] [Abstract][Full Text] [Related]